Glypressin (Terlipressin Acetate)

Glypressin is used in clinical practice to manage complications of advanced liver disease and severe circulatory disturbances where vasoconstriction is required.

• Acute variceal hemorrhage in patients with cirrhosis, administered intravenously to achieve rapid hemostasis and control bleeding.
• Hepatorenal syndrome type 1, used as a short‑term vasoconstrictor to improve renal perfusion while awaiting definitive therapy.
• Severe portal hypertension, where reduction of portal venous pressure helps to prevent the development of new varices.
• Prevention of early rebleeding after endoscopic band ligation, providing additional vascular tone during the critical post‑procedure period.
• Refractory septic shock when catecholamines are insufficient, offering an alternative mechanism to raise systemic vascular resistance.

The safety profile of Glypressin reflects its potent vasoconstrictive action; side effects are reported across a range of frequencies and may be related to the degree of vascular tone achieved during treatment.

Common

• Headache or facial flushing, often mild and transient.
• Nausea, vomiting or abdominal discomfort that may resolve after infusion.
• Hypertension or a temporary rise in systolic blood pressure during administration.
• Peripheral edema or mild swelling of the extremities, usually reversible.
• Dizziness or light‑headedness, especially when standing quickly.

Serious

• Cardiac arrhythmias or myocardial ischemia, requiring cardiac monitoring.
• Severe hypertension that can precipitate cerebrovascular events such as stroke.
• Ischemic necrosis of skin, digits or gastrointestinal tract, indicating critical peripheral vasoconstriction.

When prescribing Glypressin, clinicians should evaluate patient-specific factors and monitor for potential complications associated with its vasoconstrictive properties.

• Assess cardiovascular status, including history of ischemic heart disease or uncontrolled hypertension.
• Use caution in patients with peripheral vascular disease or Raynaud’s phenomenon.
• Monitor renal function closely, especially in those with pre‑existing renal impairment.
• Observe for signs of tissue ischemia, such as pain, discoloration or loss of pulse in extremities.
• Adjust dose or discontinue if severe hypertension or arrhythmias develop.
• Consider fetal risk; Glypressin is contraindicated in pregnancy unless benefits outweigh potential risks.

Glypressin may interact with other agents that influence vascular tone, cardiac rhythm or renal function; awareness of these interactions helps to minimize adverse outcomes.

Avoid

• Concomitant use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive hypertension risk.
• Combination with vasodilators (e.g., nitroglycerin) that may counteract therapeutic effect.
• Co‑administration with drugs that prolong QT interval, increasing arrhythmia potential.

Use with caution

• Concurrent catecholamines in septic shock; dose adjustments may be required.
• Diuretics or ACE inhibitors, as they may affect blood pressure stability.
• Anticoagulants, because rapid hemodynamic changes can influence bleeding risk.